Sami Uwaydat
Concepts (259)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Retinal Diseases | 8 | 2023 | 49 | 4.050 |
Why?
| Eye Injuries | 5 | 2024 | 33 | 3.470 |
Why?
| Retina | 8 | 2024 | 65 | 2.200 |
Why?
| Endophthalmitis | 4 | 2022 | 30 | 2.150 |
Why?
| Vitrectomy | 8 | 2022 | 49 | 2.070 |
Why?
| Retinal Dystrophies | 3 | 2023 | 7 | 1.850 |
Why?
| Tomography, Optical Coherence | 15 | 2023 | 148 | 1.740 |
Why?
| Retinal Degeneration | 4 | 2022 | 16 | 1.690 |
Why?
| Visual Acuity | 10 | 2022 | 143 | 1.670 |
Why?
| Drug Implants | 5 | 2020 | 35 | 1.670 |
Why?
| Chorioretinitis | 2 | 2022 | 8 | 1.630 |
Why?
| Fungemia | 2 | 2022 | 36 | 1.610 |
Why?
| Eye Proteins | 2 | 2021 | 19 | 1.600 |
Why?
| Eye Infections, Fungal | 2 | 2022 | 22 | 1.590 |
Why?
| Eye Diseases | 4 | 2023 | 35 | 1.450 |
Why?
| Dexamethasone | 4 | 2020 | 435 | 1.390 |
Why?
| Macular Degeneration | 2 | 2021 | 52 | 1.040 |
Why?
| Retinal Perforations | 2 | 2022 | 7 | 1.010 |
Why?
| Glucocorticoids | 5 | 2020 | 234 | 0.990 |
Why?
| Burns, Chemical | 1 | 2024 | 9 | 0.980 |
Why?
| Fundus Oculi | 6 | 2022 | 24 | 0.970 |
Why?
| Humans | 50 | 2024 | 54304 | 0.880 |
Why?
| Macular Edema | 3 | 2019 | 25 | 0.880 |
Why?
| Charcot-Marie-Tooth Disease | 1 | 2022 | 11 | 0.850 |
Why?
| Optic Atrophy | 1 | 2022 | 18 | 0.830 |
Why?
| Genetic Testing | 2 | 2020 | 135 | 0.830 |
Why?
| Giant Cell Arteritis | 1 | 2021 | 12 | 0.800 |
Why?
| Intraoperative Complications | 3 | 2018 | 125 | 0.790 |
Why?
| Genetic Diseases, X-Linked | 1 | 2021 | 10 | 0.790 |
Why?
| Laser Coagulation | 1 | 2021 | 27 | 0.780 |
Why?
| Manikins | 1 | 2021 | 40 | 0.760 |
Why?
| Retinal Pigment Epithelium | 2 | 2022 | 24 | 0.760 |
Why?
| Lasers, Solid-State | 1 | 2021 | 32 | 0.760 |
Why?
| Multiple Sclerosis | 1 | 2021 | 72 | 0.760 |
Why?
| Candidiasis | 1 | 2021 | 122 | 0.730 |
Why?
| Wounds, Nonpenetrating | 1 | 2021 | 90 | 0.730 |
Why?
| Anterior Chamber | 2 | 2023 | 10 | 0.720 |
Why?
| Surgical Instruments | 1 | 2019 | 34 | 0.710 |
Why?
| Electroretinography | 6 | 2023 | 20 | 0.710 |
Why?
| Fluorescein Angiography | 6 | 2022 | 30 | 0.700 |
Why?
| Choroidal Neovascularization | 2 | 2019 | 69 | 0.690 |
Why?
| Endotamponade | 2 | 2017 | 9 | 0.660 |
Why?
| Gaucher Disease | 1 | 2018 | 17 | 0.650 |
Why?
| Eyelashes | 1 | 2018 | 3 | 0.640 |
Why?
| Eyelid Diseases | 1 | 2018 | 13 | 0.630 |
Why?
| Sulfur Hexafluoride | 1 | 2017 | 3 | 0.630 |
Why?
| Eye Diseases, Hereditary | 1 | 2017 | 6 | 0.610 |
Why?
| Inheritance Patterns | 1 | 2017 | 27 | 0.600 |
Why?
| Lenses | 1 | 2016 | 7 | 0.570 |
Why?
| Urinary Catheters | 1 | 2016 | 6 | 0.560 |
Why?
| Suction | 1 | 2016 | 22 | 0.560 |
Why?
| Eye Injuries, Penetrating | 2 | 2015 | 21 | 0.520 |
Why?
| Bacillaceae | 1 | 2015 | 6 | 0.520 |
Why?
| Retrospective Studies | 13 | 2024 | 6462 | 0.520 |
Why?
| Mutation | 3 | 2022 | 1504 | 0.510 |
Why?
| Intravitreal Injections | 6 | 2020 | 40 | 0.510 |
Why?
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2016 | 142 | 0.500 |
Why?
| Aspirin | 1 | 2016 | 127 | 0.500 |
Why?
| Intraocular Pressure | 2 | 2020 | 89 | 0.500 |
Why?
| Choroid Neoplasms | 1 | 2014 | 7 | 0.490 |
Why?
| Ocular Hypotension | 1 | 2013 | 3 | 0.480 |
Why?
| Viscosupplements | 1 | 2013 | 12 | 0.480 |
Why?
| Wound Healing | 2 | 2016 | 228 | 0.480 |
Why?
| Orbital Neoplasms | 1 | 2014 | 30 | 0.480 |
Why?
| Hyaluronic Acid | 1 | 2013 | 32 | 0.470 |
Why?
| Head Injuries, Closed | 1 | 2013 | 9 | 0.470 |
Why?
| Eye Infections, Bacterial | 2 | 2011 | 35 | 0.470 |
Why?
| Physicians, Primary Care | 1 | 2013 | 43 | 0.450 |
Why?
| Antibodies, Monoclonal | 1 | 2018 | 564 | 0.450 |
Why?
| Sulfonamides | 1 | 2014 | 146 | 0.440 |
Why?
| Diabetes Complications | 1 | 2013 | 123 | 0.440 |
Why?
| Middle Aged | 14 | 2022 | 13076 | 0.430 |
Why?
| Disease Models, Animal | 2 | 2016 | 1651 | 0.430 |
Why?
| Female | 19 | 2023 | 28457 | 0.430 |
Why?
| Acute Disease | 3 | 2023 | 403 | 0.420 |
Why?
| Honey | 1 | 2011 | 8 | 0.410 |
Why?
| Keratitis | 1 | 2011 | 17 | 0.400 |
Why?
| Skin Neoplasms | 2 | 2014 | 532 | 0.400 |
Why?
| Papilledema | 2 | 2022 | 28 | 0.400 |
Why?
| Indoles | 1 | 2014 | 289 | 0.400 |
Why?
| Pseudomonas Infections | 1 | 2011 | 54 | 0.400 |
Why?
| Clinical Competence | 2 | 2013 | 444 | 0.390 |
Why?
| Panuveitis | 2 | 2021 | 6 | 0.390 |
Why?
| Male | 22 | 2023 | 27335 | 0.380 |
Why?
| Melanoma | 1 | 2014 | 313 | 0.370 |
Why?
| Attitude of Health Personnel | 1 | 2013 | 389 | 0.360 |
Why?
| Phacoemulsification | 3 | 2020 | 30 | 0.360 |
Why?
| Pedigree | 2 | 2021 | 146 | 0.350 |
Why?
| Incidence | 3 | 2022 | 1083 | 0.350 |
Why?
| Antineoplastic Agents | 2 | 2018 | 1300 | 0.340 |
Why?
| Health Knowledge, Attitudes, Practice | 1 | 2013 | 538 | 0.330 |
Why?
| Phenotype | 2 | 2021 | 820 | 0.310 |
Why?
| Fovea Centralis | 3 | 2022 | 5 | 0.310 |
Why?
| Equipment Contamination | 1 | 2007 | 26 | 0.300 |
Why?
| Ophthalmology | 3 | 2018 | 40 | 0.300 |
Why?
| Microscopy | 1 | 2007 | 66 | 0.300 |
Why?
| Ophthalmologic Surgical Procedures | 1 | 2007 | 27 | 0.290 |
Why?
| Child, Preschool | 5 | 2024 | 4161 | 0.280 |
Why?
| Adult | 11 | 2023 | 14189 | 0.270 |
Why?
| Aged | 9 | 2023 | 10054 | 0.250 |
Why?
| Child | 8 | 2024 | 7372 | 0.240 |
Why?
| Paracentesis | 1 | 2023 | 10 | 0.240 |
Why?
| Retinol-Binding Proteins | 1 | 2023 | 5 | 0.240 |
Why?
| Myopia | 1 | 2023 | 8 | 0.240 |
Why?
| Retinoschisis | 1 | 2023 | 3 | 0.230 |
Why?
| Risk Factors | 4 | 2021 | 3934 | 0.220 |
Why?
| Young Adult | 5 | 2023 | 4313 | 0.220 |
Why?
| Vascular Endothelial Growth Factor A | 3 | 2020 | 233 | 0.210 |
Why?
| Scotoma | 1 | 2021 | 8 | 0.200 |
Why?
| Macula Lutea | 1 | 2021 | 6 | 0.200 |
Why?
| Albinism, Oculocutaneous | 1 | 2021 | 5 | 0.200 |
Why?
| Temporal Arteries | 1 | 2021 | 15 | 0.200 |
Why?
| Ophthalmoscopy | 1 | 2021 | 19 | 0.200 |
Why?
| Vision Disorders | 2 | 2022 | 74 | 0.200 |
Why?
| Retinal Detachment | 1 | 2021 | 23 | 0.190 |
Why?
| Exons | 1 | 2021 | 105 | 0.190 |
Why?
| Choroiditis | 1 | 2020 | 10 | 0.190 |
Why?
| Eye Abnormalities | 1 | 2020 | 22 | 0.180 |
Why?
| Hyperlipoproteinemia Type I | 1 | 2000 | 2 | 0.180 |
Why?
| Conjunctival Diseases | 1 | 2000 | 6 | 0.180 |
Why?
| Infant | 3 | 2024 | 3832 | 0.180 |
Why?
| Internship and Residency | 2 | 2013 | 502 | 0.180 |
Why?
| Eyeglasses | 1 | 2019 | 10 | 0.180 |
Why?
| Vitreoretinal Surgery | 1 | 2019 | 8 | 0.180 |
Why?
| Crohn Disease | 1 | 2020 | 97 | 0.180 |
Why?
| Intraoperative Period | 1 | 2019 | 51 | 0.180 |
Why?
| Disease Management | 1 | 2021 | 184 | 0.180 |
Why?
| Emergency Service, Hospital | 1 | 2024 | 540 | 0.170 |
Why?
| Choroid | 1 | 2019 | 26 | 0.170 |
Why?
| High-Throughput Nucleotide Sequencing | 1 | 2021 | 206 | 0.170 |
Why?
| Optic Disk | 1 | 2019 | 25 | 0.170 |
Why?
| Laser Therapy | 1 | 2019 | 91 | 0.170 |
Why?
| Amaurosis Fugax | 1 | 2018 | 3 | 0.170 |
Why?
| Vision, Ocular | 1 | 2018 | 14 | 0.170 |
Why?
| Biopsy | 1 | 2021 | 693 | 0.170 |
Why?
| Retinal Artery Occlusion | 1 | 2018 | 8 | 0.170 |
Why?
| Pandemics | 1 | 2024 | 593 | 0.160 |
Why?
| Glucosylceramidase | 1 | 2018 | 11 | 0.160 |
Why?
| Enzyme Replacement Therapy | 1 | 2018 | 19 | 0.160 |
Why?
| Imaging, Three-Dimensional | 1 | 2019 | 172 | 0.160 |
Why?
| Vascular Malformations | 1 | 2020 | 101 | 0.160 |
Why?
| Visual Fields | 1 | 2018 | 56 | 0.160 |
Why?
| Fluocinolone Acetonide | 1 | 2017 | 6 | 0.160 |
Why?
| Prone Position | 1 | 2017 | 38 | 0.150 |
Why?
| Consanguinity | 1 | 2017 | 15 | 0.150 |
Why?
| Genes, Recessive | 1 | 2017 | 18 | 0.150 |
Why?
| Uveitis | 1 | 2017 | 28 | 0.150 |
Why?
| Heterozygote | 1 | 2017 | 96 | 0.150 |
Why?
| Fibrinolytic Agents | 1 | 2018 | 139 | 0.150 |
Why?
| Thrombolytic Therapy | 1 | 2018 | 127 | 0.150 |
Why?
| Follow-Up Studies | 5 | 2019 | 2389 | 0.150 |
Why?
| Air | 1 | 2016 | 26 | 0.140 |
Why?
| DNA Mutational Analysis | 1 | 2017 | 217 | 0.140 |
Why?
| Minerals | 1 | 2016 | 36 | 0.140 |
Why?
| Recombinant Proteins | 1 | 2018 | 570 | 0.140 |
Why?
| Genetic Association Studies | 1 | 2017 | 136 | 0.140 |
Why?
| Adolescent | 4 | 2022 | 6896 | 0.140 |
Why?
| Sodium Chloride | 1 | 2016 | 67 | 0.140 |
Why?
| Acetates | 1 | 2016 | 50 | 0.140 |
Why?
| Vascular Surgical Procedures | 1 | 2018 | 178 | 0.140 |
Why?
| Patient Selection | 1 | 1998 | 284 | 0.140 |
Why?
| Equipment Failure | 1 | 2016 | 70 | 0.140 |
Why?
| Chemokine CCL2 | 1 | 2016 | 79 | 0.140 |
Why?
| United States | 2 | 2024 | 5204 | 0.140 |
Why?
| Enzyme-Linked Immunosorbent Assay | 1 | 2016 | 314 | 0.130 |
Why?
| Eye Foreign Bodies | 1 | 2015 | 10 | 0.130 |
Why?
| Nevus of Ota | 1 | 2014 | 3 | 0.130 |
Why?
| Scleral Diseases | 1 | 2014 | 3 | 0.130 |
Why?
| Eye Neoplasms | 1 | 2014 | 10 | 0.130 |
Why?
| Siblings | 1 | 2014 | 38 | 0.120 |
Why?
| Vision, Monocular | 1 | 2013 | 1 | 0.120 |
Why?
| Injections, Intraocular | 1 | 2013 | 7 | 0.120 |
Why?
| Liver Neoplasms | 1 | 2018 | 352 | 0.120 |
Why?
| Diagnostic Techniques, Ophthalmological | 1 | 2013 | 22 | 0.120 |
Why?
| Proto-Oncogene Proteins B-raf | 1 | 2014 | 92 | 0.120 |
Why?
| Cell Line | 1 | 2016 | 1152 | 0.110 |
Why?
| Activities of Daily Living | 1 | 2013 | 204 | 0.110 |
Why?
| Animals | 4 | 2018 | 14402 | 0.110 |
Why?
| Treatment Outcome | 4 | 2020 | 5609 | 0.110 |
Why?
| Autistic Disorder | 1 | 2013 | 135 | 0.110 |
Why?
| Diet | 1 | 2016 | 584 | 0.100 |
Why?
| Rats, Inbred Lew | 1 | 2011 | 68 | 0.100 |
Why?
| Endotoxins | 1 | 2011 | 37 | 0.100 |
Why?
| Administration, Topical | 1 | 2011 | 71 | 0.100 |
Why?
| Cornea | 1 | 2011 | 62 | 0.100 |
Why?
| Referral and Consultation | 1 | 2013 | 307 | 0.100 |
Why?
| Pseudomonas aeruginosa | 1 | 2011 | 86 | 0.100 |
Why?
| Retinal Vessels | 2 | 2021 | 13 | 0.100 |
Why?
| Mice, Inbred C57BL | 1 | 2016 | 2002 | 0.090 |
Why?
| RNA | 1 | 2011 | 202 | 0.090 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 674 | 0.090 |
Why?
| Magnetic Resonance Imaging | 2 | 2014 | 1616 | 0.080 |
Why?
| Angiogenesis Inhibitors | 2 | 2020 | 203 | 0.080 |
Why?
| Lens Implantation, Intraocular | 2 | 2018 | 22 | 0.080 |
Why?
| Cytokines | 1 | 2011 | 677 | 0.080 |
Why?
| Vitreoretinopathy, Proliferative | 1 | 2007 | 2 | 0.080 |
Why?
| Scleral Buckling | 1 | 2007 | 4 | 0.080 |
Why?
| Cross-Sectional Studies | 1 | 2013 | 1693 | 0.080 |
Why?
| Orbital Cellulitis | 1 | 2007 | 9 | 0.080 |
Why?
| Aged, 80 and over | 3 | 2020 | 3430 | 0.080 |
Why?
| Corneal Diseases | 1 | 2007 | 14 | 0.080 |
Why?
| Microsurgery | 1 | 2007 | 35 | 0.080 |
Why?
| Fungi | 1 | 2007 | 48 | 0.070 |
Why?
| Postoperative Complications | 1 | 2013 | 1035 | 0.070 |
Why?
| Aptamers, Nucleotide | 1 | 2006 | 7 | 0.070 |
Why?
| Cross Infection | 1 | 2007 | 109 | 0.070 |
Why?
| Prosthesis-Related Infections | 1 | 2007 | 111 | 0.070 |
Why?
| Diagnostic Imaging | 1 | 2007 | 185 | 0.070 |
Why?
| Vitamins | 1 | 2006 | 71 | 0.070 |
Why?
| Bacteria | 1 | 2007 | 257 | 0.060 |
Why?
| Mice | 1 | 2016 | 6428 | 0.060 |
Why?
| Rats | 1 | 2011 | 3417 | 0.060 |
Why?
| Atrophy | 1 | 2023 | 40 | 0.060 |
Why?
| Molecular Biology | 1 | 2022 | 31 | 0.050 |
Why?
| Retinal Ganglion Cells | 1 | 2022 | 23 | 0.050 |
Why?
| GTP-Binding Proteins | 1 | 2022 | 94 | 0.050 |
Why?
| Smoking | 1 | 2006 | 552 | 0.050 |
Why?
| Diagnosis, Differential | 2 | 2007 | 1143 | 0.050 |
Why?
| Socioeconomic Factors | 1 | 2023 | 638 | 0.050 |
Why?
| Hypertension | 1 | 2006 | 564 | 0.050 |
Why?
| Health Status Disparities | 1 | 2023 | 219 | 0.050 |
Why?
| Vibration | 1 | 2000 | 14 | 0.050 |
Why?
| Epiretinal Membrane | 1 | 2020 | 9 | 0.050 |
Why?
| Retinal Vein | 1 | 2000 | 3 | 0.050 |
Why?
| Retinal Artery | 1 | 2000 | 5 | 0.050 |
Why?
| Retinal Vein Occlusion | 1 | 2020 | 12 | 0.050 |
Why?
| Iris | 1 | 2000 | 10 | 0.050 |
Why?
| Membrane Proteins | 1 | 2022 | 389 | 0.050 |
Why?
| Conjunctiva | 1 | 2000 | 19 | 0.050 |
Why?
| Diabetic Retinopathy | 1 | 2020 | 41 | 0.040 |
Why?
| Healthcare Disparities | 1 | 2023 | 270 | 0.040 |
Why?
| Cholesterol | 1 | 2000 | 150 | 0.040 |
Why?
| Fatty Acids | 1 | 2000 | 175 | 0.040 |
Why?
| Occupational Diseases | 1 | 2000 | 93 | 0.040 |
Why?
| Triglycerides | 1 | 2000 | 192 | 0.040 |
Why?
| Pseudophakia | 1 | 2018 | 11 | 0.040 |
Why?
| State Medicine | 1 | 2018 | 17 | 0.040 |
Why?
| Equipment Design | 1 | 2019 | 318 | 0.040 |
Why?
| Time-to-Treatment | 1 | 2018 | 74 | 0.040 |
Why?
| Developing Countries | 1 | 1998 | 51 | 0.040 |
Why?
| Drug Combinations | 1 | 2016 | 128 | 0.040 |
Why?
| Video Recording | 1 | 2016 | 90 | 0.030 |
Why?
| Electronic Health Records | 1 | 2018 | 203 | 0.030 |
Why?
| Comorbidity | 1 | 2018 | 666 | 0.030 |
Why?
| Databases, Factual | 1 | 2018 | 683 | 0.030 |
Why?
| Pilot Projects | 1 | 1998 | 805 | 0.030 |
Why?
| Prospective Studies | 2 | 2000 | 2604 | 0.030 |
Why?
| Time Factors | 1 | 2019 | 3207 | 0.030 |
Why?
| Electrooculography | 1 | 2007 | 14 | 0.020 |
Why?
| Inclusion Bodies | 1 | 2007 | 23 | 0.020 |
Why?
| Lymphocytes | 1 | 2007 | 168 | 0.020 |
Why?
| Lipids | 1 | 2007 | 178 | 0.020 |
Why?
| Cytochrome P-450 Enzyme System | 1 | 2007 | 192 | 0.020 |
Why?
| Fibroblasts | 1 | 2007 | 386 | 0.020 |
Why?
| Tomography, X-Ray Computed | 1 | 2007 | 1222 | 0.010 |
Why?
| Corneal Opacity | 1 | 2000 | 4 | 0.010 |
Why?
| Pigmentation Disorders | 1 | 2000 | 8 | 0.010 |
Why?
| Vitreous Body | 1 | 2000 | 16 | 0.010 |
Why?
| Trabecular Meshwork | 1 | 2000 | 10 | 0.010 |
Why?
|
|
Uwaydat's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|